Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced UroScience

This article was originally published in The Gray Sheet

Executive Summary

Minnesota federal judge dismisses suit against the firm and founder Timothy Lawin Sept. 30. Brought by Uroplasty in August 1998, the suit alleged that Lawin had misappropriated Uroplasty's pyrolytic, carbon-coated micro-bead technology for use in the Durasphere injectable stress urinary incontinence product. Durasphere was approved by FDA Sept. 13 (1"The Gray Sheet" Sept. 27, p. 14). U.S. district court Judge Michael Davis rules that Uroplasty failed to show evidence that the firm was ever involved with the development of the technology

You may also be interested in...



Advanced UroScience Durasphere Post-Approval Study Focuses On Durability

Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.

QUOTED. 18 June 2021. Harith Rajagopalan.

Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.

Will COVID Finally Help US FDA And Sponsors Overcome Their ‘Angst’ On Innovative Trial Designs?

The ‘sea change’ inside White Oak should be seen as very encouraging for sponsors, FDA official says.

UsernamePublicRestriction

Register

MT012409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel